%0 Journal Article
%T Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa
%A Berry I. Bongenya
%A Charlotte Tshinguta
%A Benoit O. Kabengele
%A Marie-Th¨Śr¨¨se A. S. Sombo
%A Guy M. M. Bumoko
%A Mariano M. Lusakibanza
%A Gauthier K. Mesia
%A Erick N. Kamangu
%J World Journal of AIDS
%P 161-170
%@ 2160-8822
%D 2023
%I Scientific Research Publishing
%R 10.4236/wja.2023.134013
%X <strong>Context:</strong> The appointment of the M6 is crucial because it is an indicator of the prognosis of the evolution of the care and the decision-making on the continuation of the AntiRetroViral Treatment. <strong>Objective:</strong> The objective of this study is therefore to present the virological and molecular profile of People Living with HIV under treatment with Dolutegravir 6 months after being put on ART in Kinshasa. <strong>Methods:</strong> The present study is a cross-sectional view at the sixth month of a prospective cohort to determine the virological and molecular profile of People Living with HIV (PLHIV) after 6 months of ART based on Dolutegravir (DTG) in Kinshasa. A sample of 5 mL of blood was taken from all HIV patients included. The collection of biological data was carried out under the same conditions as at inclusion. After extraction, Quantitative Real-Time PCR was carried out to determine the quantity of HIV RNA in the samples according to the protocols previously described. Reverse Transcription PCR (RT-PCR) and Nested PCR were carried out to amplify the regions of interest for Protease and Reverse Transcriptase for sequencing. <strong>Results: </strong>The median VL value was 2.92 log<sub>10</sub> RNA copies/mL. With 17.75<span style=\"white-space:nowrap;\">%</span> of patients experiencing major failure of first-line treatment. Subtype A is dominant with 13 cases (20.98<span style=\"white-space:nowrap;\">%</span>); followed by CRF_02AG (16.13<span style=\"white-space:nowrap;\">%</span>), subtypes C (14.52<span style=\"white-space:nowrap;\">%</span>), D (9.68<span style=\"white-space:nowrap;\">%</span>) and K (6.45<span style=\"white-space:nowrap;\">%</span>). The K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) mutations were listed as existing mutations for Nucleotide Reverse Transcriptase Inhibitors. <strong>Conclusion:</strong> After 6 months of ART, 59.67<span style=\"white-space:nowrap;\">%</span> of People Living with HIV on Tenofovir-Lamivudine-Dolutegravir is in therapeutic success while 40.33<span style=\"white-space:nowrap;\">%</span> are in a state of treatment failure. Subtype A remains dominant in the population of PLHIV. Resistance mutations were detected for Lamivudine and Tenofovir, but none for Dolutegravir.
%K Virological Profile
%K Molecular
%K PLHIV
%K 6 Months of ART
%K Dolutegravir
%K Kinshasa
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=128987